Results 211 to 220 of about 1,415,739 (335)

Table 1_Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials.docx

Shan Gao (46743), Xingxing Xie (6293498), Ling Fan (2215240), Linyuan Yu (8929973)   +3 more
openalex   +1 more source

Odontoblast-like MDPC-23 cells produce pro-inflammatory IL-6 in response to lipoteichoic acid and express the antimicrobial peptide CRAMP [PDF]

, 2019
Karin Odlén, Felicia Fält, Sara Dahl, Alexandra Aidoukovitch, Dan Ericson, Bengt‐Olof Nilsson, Anders Hedenbjörk‐Lager   +6 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Mirikizumab: a landmark in IL-23-targeted therapy for ulcerative colitis. [PDF]

Ann Med Surg (Lond)
Iqbal MU, Shafquat E, Khan MO, Abu Nahla U.   +3 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

PO:01:010 | Survival of second-line treatment with tnf inhibitors vs il-23 inhibitors after failure of a first tnf inhibitor: a real-life observational study from the italian multicenter birra cohort in patients with psoriatic arthritis

Reumatismo
Background. Since 2021, IL-23 inhibitors (IL-23i) such as guselkumab, and since 2022 risankizumab, have been available for the treatment of psoriatic arthritis (PsA). However, after failure of a first tumor necrosis factor inhibitor (TNFi), switching to
Società Italiana di Reumatologia
doaj  

Rare pediatric Saccharomyces cerevisiae fungemia with neutralizing anti-IL-23 autoantibodies: a case report. [PDF]

BMC Pediatr
Zhou Y, Song R, Chen X, Cao Q.
europepmc   +1 more source

The IL-23/IL-17 axis as a therapeutic target

, 2013
Kojiro Sato
openalex   +2 more sources

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Investigation of the Relationships Between IL-12B and IL-23 Receptor Polymorphisms with Behçet's Disease in a Turkish Population. [PDF]

Int J Mol Sci
Arıkan S, Öztürk O, Atalay A, Atalay EÖ.   +3 more
europepmc   +1 more source